EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 350 filers reported holding EXELIXIS INC in Q4 2020. The put-call ratio across all filers is 2.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,747,542 | +90.7% | 308,812 | +66.8% | 0.01% | +100.0% |
| Q2 2023 | $3,537,376 | +5.3% | 185,106 | +6.9% | 0.00% | 0.0% |
| Q1 2023 | $3,359,793 | +14.5% | 173,096 | -5.4% | 0.00% | 0.0% |
| Q4 2022 | $2,933,652 | -68.1% | 182,896 | -68.5% | 0.00% | -66.7% |
| Q3 2022 | $9,186,000 | -29.4% | 579,935 | -7.2% | 0.01% | -20.0% |
| Q2 2022 | $13,017,000 | -20.3% | 625,235 | -13.2% | 0.02% | 0.0% |
| Q1 2022 | $16,323,000 | +8.6% | 720,035 | -12.5% | 0.02% | +15.4% |
| Q4 2021 | $15,034,000 | +21.8% | 822,435 | +40.8% | 0.01% | 0.0% |
| Q3 2021 | $12,346,000 | +21.4% | 583,998 | -3.2% | 0.01% | +30.0% |
| Q2 2021 | $10,169,000 | -28.6% | 603,498 | -4.2% | 0.01% | -37.5% |
| Q1 2021 | $14,238,000 | +51.9% | 630,278 | +34.9% | 0.02% | +45.5% |
| Q4 2020 | $9,375,000 | +22.2% | 467,123 | +48.9% | 0.01% | 0.0% |
| Q3 2020 | $7,672,000 | +1.4% | 313,777 | -1.5% | 0.01% | 0.0% |
| Q2 2020 | $7,563,000 | +87.3% | 318,577 | +35.9% | 0.01% | +57.1% |
| Q1 2020 | $4,037,000 | +84.8% | 234,454 | +89.2% | 0.01% | +133.3% |
| Q4 2019 | $2,184,000 | -20.0% | 123,948 | -19.7% | 0.00% | -25.0% |
| Q3 2019 | $2,731,000 | -13.2% | 154,448 | +5.0% | 0.00% | -20.0% |
| Q2 2019 | $3,145,000 | +11.2% | 147,148 | +23.8% | 0.01% | +25.0% |
| Q1 2019 | $2,829,000 | +135.9% | 118,848 | +95.0% | 0.00% | +100.0% |
| Q4 2018 | $1,199,000 | -0.8% | 60,948 | -10.7% | 0.00% | 0.0% |
| Q3 2018 | $1,209,000 | -41.0% | 68,248 | -28.3% | 0.00% | -33.3% |
| Q2 2018 | $2,048,000 | -53.1% | 95,148 | -51.7% | 0.00% | -57.1% |
| Q1 2018 | $4,365,000 | -17.2% | 197,080 | +13.6% | 0.01% | -12.5% |
| Q4 2017 | $5,274,000 | +24.5% | 173,480 | -0.7% | 0.01% | +33.3% |
| Q3 2017 | $4,235,000 | +5.0% | 174,780 | +6.7% | 0.01% | 0.0% |
| Q2 2017 | $4,034,000 | -8.5% | 163,780 | -19.5% | 0.01% | -14.3% |
| Q1 2017 | $4,409,000 | +27.5% | 203,468 | -12.3% | 0.01% | +16.7% |
| Q4 2016 | $3,459,000 | +0.0% | 231,968 | -14.2% | 0.01% | 0.0% |
| Q3 2016 | $3,458,000 | +30.6% | 270,368 | -20.2% | 0.01% | +20.0% |
| Q2 2016 | $2,647,000 | +2.4% | 338,868 | -47.6% | 0.01% | 0.0% |
| Q1 2016 | $2,586,000 | -30.8% | 646,500 | -2.4% | 0.01% | -28.6% |
| Q4 2015 | $3,737,000 | +3.4% | 662,500 | +2.8% | 0.01% | 0.0% |
| Q3 2015 | $3,614,000 | +157.4% | 644,200 | +72.5% | 0.01% | +133.3% |
| Q2 2015 | $1,404,000 | +36.7% | 373,500 | -6.6% | 0.00% | +50.0% |
| Q1 2015 | $1,027,000 | +107.5% | 399,800 | +16.4% | 0.00% | +100.0% |
| Q4 2014 | $495,000 | -3.1% | 343,500 | +2.8% | 0.00% | 0.0% |
| Q3 2014 | $511,000 | -54.8% | 334,100 | +0.2% | 0.00% | -50.0% |
| Q2 2014 | $1,130,000 | -12.0% | 333,300 | -8.1% | 0.00% | 0.0% |
| Q1 2014 | $1,284,000 | -15.1% | 362,700 | +47.0% | 0.00% | -33.3% |
| Q4 2013 | $1,512,000 | +40.3% | 246,700 | +33.2% | 0.00% | +50.0% |
| Q3 2013 | $1,078,000 | +40.2% | 185,200 | +9.4% | 0.00% | 0.0% |
| Q2 2013 | $769,000 | – | 169,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |